Buzz: GlaxoSmithKline interested in BioMarin buyout?

GlaxoSmithKline ($GSK) was rumored to be interested in Human Genome Sciences ($HGSI) for several years before it actually got down to a brass-knuckles bid for its longstanding biotech partner. Now The Telegraph in the U.K. is reporting that the market buzz indicates that GSK is in talks with BioMarin ($BMRN), the rare disease drug outfit that has been snapping up programs in recent months. And the GSK gossip follows a rumor that Shire ($SHPGY), which has its own rare disease drug portfolio to consider, could be in the hunt for BioMarin. Rare diseases have been growing steadily more attractive to developers over the past few years. But none of this rises to the level of insider info, which helps explain why the biotech's stock is only up less than three percent this morning. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.